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Abstract
Background The leukotriene receptor antagonist montelukast has been shown to rejuvenate aged brains in rats; however, data 
on humans are still scarce. Objective To investigate if montelukast may alleviate degenerative neurological changes using 
a register data. Setting Norwegian registry data analyses. Method The present observational study was based on data from 
the Norwegian Prescription Database and the Tromsø Study. The former has information regarding the use of prescription 
medicine; the latter includes tests for brain function such as subjective memory and finger-tapping. Multivariate linear regres-
sion analyses were performed to see how the use of various medications correlated with the test results, correcting for likely 
confounders. Main outcome measure Results on seven different tests considered relevant for neurological health were used 
as outcome. Results Previous use of montelukast correlated with improved scores on cognitive or neurological functioning 
(F = 2.20, p = 0.03 in a multivariate test). A range of other medications were tested with the same algorithm, including drugs 
acting on the immune system, but none of them correlated with (overall) significantly improved test results. Conclusion 
The present data suggest that montelukast may alleviate degenerative neurological changes associated with human aging.
Keywords Anti-inflammatory medication · Dementia · Leukotriene · Montelukast · Neurological decline · Prescription 
database
Impacts on practice
• The data suggest that montelukast may postpone mental 
aging.
• The dosage used for asthma may not be optimal for pos-
sible effects on the brain.
• The data should help initiate a clinical trial to examine 
the effect of montelukast on aging.
Introduction
The term ‘inflammaging’ has been coined for an elevated 
level of low-grade and sterile inflammation [1], which has 
been associated with age-related decline [2]. That is, inflam-
matory processes may be causally involved in the aging pro-
cess in general, and in chronic neurodegenerative diseases 
such as dementias in particular [3–6]. In the case of demen-
tias, inflammation could be one of the early pathological 
triggers [7]. Consequently, anti-inflammatory interventions 
have been proposed for treatment and/or prevention of age-
related diseases [8].
Targets for potential anti-inflammatory drugs are, 
among others, the pathways of the classical lipid-mediators 
of inflammation. These are for one, the arachidonic acid-
derived prostaglandins, a prominent pathway targeted by 
Cox1/2 inhibitors; and two, the leukotrienes, targeted by 
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leukotriene receptor antagonists. The leukotriene antagonists 
were developed to treat asthma.
The Cox1/2 inhibitors are included in the umbrella term 
non-steroidal anti-inflammatory drugs (NSAIDs) In addition 
to these drugs, cortisone-based steroids could be candidates 
to address inflammaging, although they have, in addition 
to their anti-inflammatory effects also immune-suppressive 
activities. In the context of neurodegenerative diseases, 
NSAIDs have been associated with a reduced risk of demen-
tia [9, 10]. On the other hand, a systematic review concluded 
that there was no evidence for clinical benefits from the use 
of NSAIDs or steroidal drugs in the treatment of patients 
with dementia [11]. This conclusion, however, does not rule 
out a preventive effect, as the underlying pathology in age-
related diseases presumably starts years before the onset of 
symptoms.
In our recent work, using the Norwegian Prescription 
Database [NorPD], we identified the leukotriene receptor 
antagonist montelukast as a candidate to reduce the risk 
of developing dementias [12]. Indeed, a recent case report 
supports the idea that montelukast might promote cognitive 
function in patients with dementias [13]. In line with this 
idea, montelukast treatment restored learning and memory 
in aged rats, involving a reduction in neuroinflammation, but 
also a re-activation of neurogenesis as well as a restoration 
of the blood–brain-barrier integrity [14].
Aim of the study
The question of whether a particular medication has a posi-
tive (or negative) effect on aging is difficult to resolve; for 
one, because it is ethically questionable to set up clinical tri-
als that involve the use of prescription medicine on healthy 
individuals; and two, because it would require following 
individual users over many years. Thus, at least for initial 
investigations, analyses of data from relevant databases seem 
to be the best option. A clinical trial will be more acceptable 
if there is sufficient indirect evidence suggesting a protec-
tive effect.
In the present study, we linked information on drug use 
from NorPD with data on neurological health from the 
Tromsø study [15]. The linked dataset allowed for consid-
ering the effect of any type of medication on brain perfor-
mance, thus the effect of montelukast was compared with 
that of other drugs affecting the immune system, focusing on 
drugs that are typically prescribed over an extended period 
and to a reasonable number of individuals.
Ethics approval
The Norwegian Regional Committees for Medical and 
Health Research Ethics (REK sør-øst) accepted the Pro-
ject on 18.02.2016 (case 2016/134) with extensions dated 
17.03.2017. The project received concession from the 
Norwegian Data Inspectorate on 21.03.2017 (reference 
17/10487). The research was carried out in accordance with 
relevant guidelines and regulations. The present study did 
not use data in a form that was person-identifiable. The 
Tromsø Study includes relevant informed consent. The data 
files are only available at designated computers within the 
Norwegian Institute of Public Health.
Method
Study design
This is an observational study where we relied on data from 
two existing databases: NorPD (www.norpd .no) and the 
Tromsø Study. The Tromsø Study (www.troms ostud y.com) 
is a prospective cohort study with primarily Caucasian par-
ticipants [15]. It includes seven surveys (1974–2016], each 
contains a variety of data concerning both physical and men-
tal health. Data from the last survey, Tromsø 7 (2015–16), 
formed the basis for the present analyses. Data from Tromsø 
6 (2007–08) were investigated to see if they diverged from 
the results of Tromsø 7. Only individuals 60 years or older 
at the time of testing were included.
The 2018 version of the NorPD contains information 
about all prescribed drugs dispensed at pharmacies to indi-
viduals in Norway from January 1, 2004 to December 31, 
2017. The NorPD classify medication according to the Ana-
tomical Therapeutic Chemical (ATC) system [16]. Some of 
the relevant drugs, particularly acetylsalicylic acid, paraceta-
mol, and NSAIDs, are sold both as prescriptions and over-
the-counter. We expect that people receiving prescriptions 
have more severe conditions, and are more likely to be long 
term-users.
The Tromsø Study was linked with data from the NorPD 
by using the Norwegian ID system. The task was performed 
by Statistics Norway (https ://www.ssb.no/en/) in order to 
ensure that the resulting file did not contain any person-
identifiable information. The linked file was used to investi-
gate how the use of various classes of drugs correlated with 
score on cognition and neurological tests. Multivariate lin-
ear regression analyses were performed for this purpose as 
detailed below. As the users of a particular medication may 
have a reduced general health compared to non-users, which 
suggests potentially lower scores on cognitive tests, we con-
sidered it pertinent to adjust for health-related confounders.
Independent and dependent variables
The ATC system offers five levels of classification, the 
lowest level being specific, active substances. Higher lev-
els were used in cases where individual substances did not 
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have a sufficient number of users. That is, as independ-
ent variables we focused on the following medications 
(ATC code): montelukast (R03DC03), anti-inflammatory 
and anti-rheumatic products, non-steroids (M01A), glu-
cocorticoids (H02AB), immunosuppressants (L04), ace-
tylsalicylic acid (B01AC06), coxibs (M01AH), inhalation 
asthma medicine (R03AK and R03BA), and paracetamol 
(N01BE01). A range of medications affecting the nervous 
system were tested using the same algorithm, including 
subgroups of analgesics (N02), antiepileptics (N03), anti-
parkinson drugs (N04), psycholeptics (N05), psykoanalep-
tics (N06), antibacterial agents (J01), and antiviral agents 
(J05).
Only individuals that received two or more prescriptions 
prior to the date of testing were considered users. Relatively 
few people received only a single prescription, and we were 
uncertain as to whether these individuals had actually taken 
the drug. The reference group for each drug was those 
who had received one or none prescriptions of the drug in 
question.
The data indicating cognitive and neurological function-
ing came from seven different tests in the Tromsø Study 
(Table 1). Four are purely cognitive: Mini-Mental State 
(MMS) examination [17], Digit-symbol coding (part of the 
Wechsler adult intelligence scale used to examine psycho-
motor speed, attention, and mental flexibility [18]), Words 
(Word-test part 1, immediate free recall of 12 nouns), and 
Subjective memory (memory as assessed by the subject 
[19]). The latter test was included in Part 1 of Tromsø 7 
and had consequently a higher number of participants than 
the other tests (Part 2), which were on a later day and for a 
subgroup of the participants.
Three tests were considered relevant for neurological 
competence: Short Physical Performance Battery (SPPB) 
[20], Balance (‘Flamingo’ test, the time subject can stand on 
one foot with eyes closed), and Finger-tapping (tap as many 
times as possible in 10 s with index finger [21]). These three 
tests concern coordinated use of muscles where, presumably, 
the neurological input is vital for the result. In addition, we 
used measurement of grip strength [22] as a control, con-
sidering this test to focus on muscle strength rather than 
neurology.
All the above variables were treated as continuous and 
without any particular reference. On all tests, a high score 
implies improved performance. The number of participants 
and test scores for montelukast users and their controls (non-
montelukast users) are shown in Table 1.
The scores Digit-symbol coding, Finger-tapping and Grip 
strength were reasonably normal distributed; while MMS, 
Words, Subjective memory, SPPB and Balance were further 
from normal distribution. We provided robust estimates of 
variance, as this strategy is considered to rely less on normal 
distribution, but may lead to lower precision.
Confounders
The linked data file allowed for the examination of con-
founders in the form of: age, sex, education, general health, 
number of diseases, smoking, and the total number of medi-
cines taken (in the form of Defined Daily Doses (DDDs). 
All these variables, with the exception of age and DDDs, 
were self-reported. A DDD is the expected average daily 
maintenance dose for the main indication of a drug [23]. 
In the present analyses, DDDs refer to the total number of 
medicines, based on the DDD definition, taken per day aver-
aged over the period from the start of the NorPD in 2004 
to the time of attendance. DDDs were used as a proxy for 
health status. The authors are aware that it is not an ideal 
proxy, but felt it desirable to include a health parameter that 
did not rely on self-report. The version of ATC/DDD used 
was the one available from WHO as of January 1, 2018. The 
Table 1  Results of tests for montelukast and their controls
The scores for controls were the same as for the complete cohort 
of individuals aged 60 or above. Data on the covariates used in the 
analyses are given below. SD standard deviation, N number of par-
ticipants, MMS mini-mental state, SPPB short physical performance 
battery, DDD defined daily dose
a This test was performed on a previous day and with a larger num-
ber of participants. The covariates data reflect the other tests, but 
the numbers were not appreciably different in the case of Subjective 
memory
Test Range Control Montelukast
Score (SD) N Score (SD) N
Cognitive
 MMS (0, 30) 27.6 (2.3) 5106 27.6 (2.3) 144
 Digit-symbol 
coding
(0, 79) 38.7 (11.1) 4989 38.9 (9.8) 141
 Words (0, 12) 6.8 (1.9) 5093 6.9 (1.8) 143
 Subjective 
 memorya
(0, 5) 3.9 (1.1) 8045 3.9 (1.1) 220
Neurological
 SPPB (0, 12) 11.1 (1.6) 5181 11.2 (1.4) 146
 Balance (0, 80) 4.8 (5.4) 4684 4.4 (4.7) 129
 Finger-tapping (19, 85) 54.5 (8.1) 4962 55.1 (7.5) 142
Control
 Grip strength (2, 71) 29.0 (10.3) 5172 27.4 (10.6) 145
Covariates
 Age (60, 84) 68.8 (6.1) 5181 68.9 (6.1) 146
 DDD (0, 20.9) 1.5 (1.7) 5181 2.9 (1.9) 146
 Number of dis-
eases
(0, 5) 0.5 (0.7) 5181 1.3 (0.8) 146
 Self-reported 
health
(1, 5) 3.7 (0.7) 5181 3.4 (0.7) 146
 Sex Male (%) 2411 (47) 5181 54 (37) 146
 Education High (%) 1968 (38) 5181 57 (39) 146
 Smoking Yes (%) 3321 (64) 5181 91 (62) 146
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confounders were added in three stages in order to visualize 
the effect of the adjustments.
Education was dichotomized into low (primary/partly 
secondary education: up to 10 years of schooling or upper 
secondary education: a minimum of 3 years) and high (Ter-
tiary education). Smoking was a category variable with the 
categories daily smokers, previously daily smoker, and never 
daily smoker. The former two were merged, thus all declared 
smokers were tested against non-smokers. Subjective health 
was based on the question “How do you in general consider 
your own health to be?” with five categories of response. 
Number of diseases was the sum of the following reported 
diseases: heart attack, heart failure, stroke, asthma, bronchi-
tis, diabetes and cancer. Health and number of diseases were 
treated as continuous variables.
Statistical analyses
We conducted analyses with Stata version 15.0. All statis-
tical tests were two-tailed and calculated at a 95% confi-
dence interval (CI). We tested differences in mean test score 
between users and nonusers of montelukast, or other medi-
cations affecting the immune system, for all the seven tests 
separately by multiple linear regression analysis. All the 
variables were added simultaneously and thus enforced. We 
subsequently adjusted for progressively more covariates. In 
Model 1, we only adjusted for age, sex and, education. In 
Model 2, DDDs were added as a proxy for general health. In 
Model 3, we also incorporated self-reported health and num-
ber of diseases as continuous variables, as well as smoking 
as a category variable. Finally, we jointly regressed all seven 
tests on the above independent variables by multivariate 
regression “mvreg”, thus testing the joint effect of various 
medications. Standard errors and significance tests were esti-
mated with the robust estimate in vce (robust).
Results
Correlations between drug use and test results
We investigated whether previous use of montelukast, or 
other drugs that affect the immune system, correlated with 
test scores related to cognitive and neurological aptitude. 
Four of the eight tests included focused on cognition, while 
three reflected neurological control of muscles. A final test, 
grip strength, was included as a control suggestive of gen-
eral senescence, but without particular relevance as to brain 
function. Table 2 lists results for montelukast users and their 
control group (the data for this control group were identi-
cal to the data for the complete cohort at the present level 
of precision), as well as data on the confounders examined. 
The number of montelukast users was below 150 for all tests 
except Subjective memory.
Individuals receiving medications are expected to have 
more health problems, and thus to score lower on both physi-
cal and mental tests. We consequently adjusted for relevant 
confounders. In order to visualize the effect of the confound-
ers, data from three models with progressively more con-
founders are presented. Table 2 offers the average differences 
in score compared to controls (β-values), as well as the 95% 
CI. A positive β implies improved performance. In Model 2 
and 3, all the scores were positive, two of them, SPPB and 
Finger-tapping, significantly so. However, the small number 
Table 2  Effect of montelukast 
on the various test scores
A positive β implies a score above the average of the control group. Differences in β was not statistically 
significant when 95% CI include both positive and negative limits. The multivariate test examines to what 
extent the scores of the first seven tests combined are significantly different from the control group. CI con-
fidence interval, MMS mini-mental state, SPPB short physical performance battery
a Adjusted for age, sex, and education
b Adjusted for age, sex, education, and DDDs
c Adjusted for age, sex, education, DDDs, self-reported health, number of diseases, and smoking
Test Model  1a Model  2b Model  3c
β 95% CI β 95% CI β 95% CI
MMS  − 0.10  − 0.46, 0.27 0.04  − 0.34, 0.41 0.10  − 0.28, 0.48
Digit-symbol coding  − 0.07  − 1.50, 1.36 1.47 0.05, 2.89 1.40  − 0.03, 2.83
Words 0.05  − 0.23, 0.34 0.20  − 0.09, 0.49 0.25  − 0.03, 0.54
Subjective memory  − 0.03  − 0.18, 0.12 0.05  − 0.10, 0.21 0.13  − 0.02, 0.28
SPPB 0.09  − 0.12, 0.30 0.34 0.13, 0.55 0.37 0.16, 0.59
Balance  − 0.34  − 1.16, 0.47 0.16  − 0.66, 0.97 0.33  − 0.50, 1.15
Finger-tapping 0.97  − 0.14, 2.08 1.85 0.74, 2.96 1.94 0.79, 3.08
Multivariate test F = 0.97 p = 0.45 F = 1.98 p = 0.05 F = 2.20 p = 0.03
Grip strength  − 0.15  − 1.21, 0.92 0.52  − 0.53, 1.58 0.62  − 0.44, 1.69
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of subjects suggested that a multivariate test, which included 
scores for all the seven tests, would be more meaningful. 
This test came out with a p = 0.05 in Model 2 and p = 0.03 
in Model 3. The grip strength of the subjects was not signifi-
cantly different from that of controls.
In order to put these results in a context, we examined 
other types of medication affecting the immune system. We 
limited the analyses to drugs, individual or ATC groups, 
with a sufficient number of users and an expected long-term 
use. As to other drugs affecting inflammatory pathways, 
we investigated ATC code M01A (anti-inflammatory and 
anti-rheumatic products, non-steroids, here referred to as 
NSAIDs), and glucocorticoids (ATC code H02AB). Only 
results based on Model 3 are shown (Table 3). The major-
ity of tests came out with negative β values. The results 
were generally not significant, with the exception of glu-
cocorticoids having a negative effect on grip strength. 
Glucocorticoids include all the commonly used steroid type 
anti-inflammatory agents. NSAIDs had been prescribed to a 
majority of the cohort, while glucocorticoids were approxi-
mately four times as common as montelukast. Similar results 
were found for coxibs (M01AH), a subgroup of NSAIDs 
with a different type of action (data not shown).
Drugs affecting other branches of the immune system 
were included in the form of immunosuppressants (ATC 
code L04, which includes inhibitors of interleukins and 
tumour necrosis factors) and acetylsalicylic acid (ATC code 
B01AC06). Their effects are shown in Table 4. In the case 
of the immunosuppressants, most of the results were posi-
tive, however, the only significantly positive effect was on 
finger-tapping, while there was a distinct, negative effect on 
grip strength. As to acetylsalicylic acid, most of the results 
were negative, except for a significant positive effect on grip 
strength. In neither case was the multivariate test significant. 
Table 3  Model 3 scores for 
NSAIDs and glucocorticoids
A positive β implies a score above the average of the control group. Differences in β was not statistically 
significant when 95% CI include both positive and negative limits. The multivariate test examines to what 
extent the scores of the first seven tests combined are significantly different from the control group; that is, 
non-users of the medication in question. NSAID non-steroidal anti-inflammatory drug, N number of partici-
pants, CI confidence interval, MMS mini-mental state, SPPB short physical performance battery
Test NSAIDs Glucocorticoids
N β 95% CI N β 95% CI
MMS 3442 0.06  − 0.07, 0.18 590  − 0.01  − 0.20, 0.18
Digit-symbol coding 3368 0.02  − 0.51, 0.54 565 0.13  − 0.63, 0.93
Words 3432  − 0.05  − 0.15, 0.05 584  − 0.10  − 0.26, 0.05
Subjective memory 5342  − 0.03  − 0.08, 0.01 933 0.08 0.00,0.16
SPPB 3495  − 0.05  − 0.13, 0.03 601  − 0.16 0.31, 0.00
Balance 3137  − 0.18  − 0.49, 0.13 492  − 0.23  − 0.62, 0.16
Finger-tapping test 3342  − 0.15  − 0.56, 0.27 568 0.16  − 0.53, 0.84
Multivariate test F = 1.35 p = 0.22 F = 1.30 p = 0.25
Grip strength 3488  − 0.19  − 0.54, 0.16 598  − 0.78  − 1.35, − 0.22
Table 4  Model 3 scores for 
immunosuppressants and 
acetylsalicylic acid
A positive β implies a score above the average of the control group. Differences in β was not statistically 
significant when 95% CI include both positive and negative limits. The multivariate test examines to what 
extent the scores of the first seven tests combined are significantly different from the control group; that 
is, non-users of the medication in question. N number of participants, CI confidence interval, MMS mini-
mental state, SPPB short physical performance battery
Test Immunosuppressants Acetylsalicylic acid
N β 95% CI N β 95% CI
MMS 172 0.21  − 0.10, 0.52 1223  − 015  − 0.32, 0.02
Digit-symbol coding 163 0.48  − 1.02, 1.99 1176  − 0.61  − 1.28, 0.07
Words 170 0.11  − 0.16, 0.37 1217  − 0.06  − 0.19, 0.07
Subjective memory 265 0.04  − 0.11, 0.18 1924  − 0.06  − 0.13, 0.01
SPPB 176  − 0.12  − 0.45, 0.21 1244 0.01  − 0.11, 0.14
Balance 144 0.16  − 0.56, 0.87 1031 0.26  − 0.12, 0.63
Finger-tapping test 164 1.27 0.18, 2.36 1174  − 0.42  − 0.96,0.12
Multivariate test F = 1.38 p = 0.21 F = 1.43 p = 0.19
Grip strength 173  − 2.0  − 3.00, − 0.90 1243 0.72 0.26, 1.18
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It should be pointed out that this test considers deviations 
from mean values, and is thus less meaningful in the case of 
mixed positive and negative effects.
Other types of drugs were tested with the same algorithm 
(Model 3), including drugs affecting the nervous system 
(N02–N06), antibacterial agents (J01), and antiviral agents 
(J05). They all came out with primarily negative effects (data 
not shown).
Discussion
We compared the effect of the leukotriene receptor antago-
nist montelukast with that of other immune-related drugs on 
cognitive and neurological fitness. The analyses were based 
on prescription data from NorPD linked with test results 
from the Tromsø Study. The results suggest that montelu-
kast might counteract age-related decline in the brain. The 
suggestion is in line with that of a previous study using data 
from NorPD alone [12]. In the present study, we had actual 
test results for brain function, rather than indirect proxies, 
but while the former study included close to 24,000 indi-
viduals on montelukast, N in the present study was generally 
below 150.
Compared to the beneficial effect of montelukast on cog-
nitive improvement observed in aged rats [14], the appar-
ent effect size in the population studies may seem small. 
There are several possible explanations as to why humans do 
not respond better, one prominent factor may be the capac-
ity of montelukast to cross the human blood brain barrier. 
Although the medication has been shown to penetrate into 
the brain of both rats and humans, entrance may be a limit-
ing factor [14, 24]. In an uncontrolled case study of individu-
als suffering from memory loss or mild dementia, daily treat-
ment with 4 × 20 mg of montelukast was reported to improve 
the condition [13]. It is worth noting that this dose is eight 
times higher than the dose prescribed to asthma patients in 
Norway. Ideally, one would hope for a clinical trial where 
healthy as well as cognitively impaired elderly subjects are 
given an elevated dose.
In the present work, the best effect of montelukast was 
on the finger-tapping test (Table 2). This test may be par-
ticularly relevant as to neuropsychological functioning. In 
an examination of stroke patients, this test was the one that 
best discriminated between survivors with intact cognitive 
function and those with cognitive decline [25].
The primary indication for the use of montelukast is as 
additional treatment of asthma in cases where inhalation 
medication is insufficient. Asthma patients have an increased 
risk of dementia [26, 27], which is why it seemed perti-
nent to control for various health variables. It is, however, 
difficult to know to what extent relevant confounders were 
included. With all the drugs tested, the results improved 
when performing the additional adjustments of Model 2 
and 3, but only in the case of montelukast did we find a 
consistent and significant positive effect. The neurological 
tests seemed to be more positive than the cognitive, which 
may reflect that the former are more accurate as to prob-
ing brain function, and/or are less likely to be distorted by 
confounders.
The perhaps most interesting part of the results was the 
distinct difference between montelukast (Table 2) and the 
other anti-inflammatory agents tested (Tables 3 and 4). It 
is worth noting that in the case of NSAIDs, previous pop-
ulation based studies suggest that this type of medication 
may protect against Alzheimer’s disease and other forms 
of dementia [9, 10]. In the present study, individuals with a 
history of NSAID prescriptions had reduced score on four 
of the seven tests. The positive scores regarding montelukast 
should be seen in relation to this observation.
In order to probe the effect of montelukast, we compared 
montelukast users to individuals who only use inhalation 
type asthma medicine (R03AK or R03BA). Montelukast 
users scored better in all tests in Model 2 and 3 (data not 
shown), but in this case the multivariate test did not come 
out as significant (p = 0.08), possibly due to the much lower 
number of controls (generally < 600). We also looked at 
results based on Tromsø 6. In this study, there were 2587 
qualifying participants. The trend, as to a positive effect of 
montelukast, was the same as in Tromsø 7, but the effects 
were not significant (data not shown).
The most positive results, next to montelukast, were 
obtained for immunosuppressants (L04) (Table 4). This is 
of interest as the group includes sirolimus (L04AA10, bet-
ter known as rapamycin), which has received considerable 
attention as an anti-aging drug [28]. Unfortunately, the num-
ber of individuals receiving this drug was too small to allow 
for a separate test.
The medication that yielded the worst scores was par-
acetamol (N01BE01, data not shown). Paracetamol is a pre-
ferred drug for pain management as it may have less side 
effects than NSAIDs. In Model 2, all the scores were nega-
tive and the multivariate test highly significant (p = 0.005). 
One should note that 40% of the sale of this medication in 
Norway is over the counter (https ://www.fhi.no/hn/legem 
iddel bruk/fakta -om-parac etamo l/), those who receive the 
drug as a prescription may have more serious health prob-
lems. The low score of paracetamol users may also reflect 
that cognitive decline weakens cortical suppression of pain 
stimuli, which may lead to higher paracetamol use [29]. A 
similar argument is relevant in the case of NSAIDs, in that 
some of the more commonly used NSAIDs, such as nap-
roxen and diclofenac, are also sold over the counter. In this 
case, however, it is assumed that a substantial majority of the 
medicinal use is based on prescriptions; as this is a cheaper 
solution for long-term users.
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Glucocorticoids had a slightly negative effect on neuro-
logical functioning, four out of seven results were negative, 
but none of them significantly so (Table 3). The negative 
effect on grip strength was, however, significant. This result 
is in line with previous observations that glucocorticoids are 
known to induce myopathy as a common side-effect [30].
Limitations
The obvious caveat regarding the present study is that the 
data are based on correlations rather than controlled experi-
ments. Moreover, the observed effect is relatively small and 
thus vulnerable to confounders we were unable to control 
for, such as to what extent the conditions associated with 
prescriptions correlate with brain function.
The low number of participants did not allow for strati-
fying on how many prescriptions were received or the time 
between drug use and testing. Information on the use of 
medicine prior to 2004 was not available; neither was over-
the-counter drugs and medications given to patients in nurs-
ing homes or hospitals.
Conclusion
The present analyses add evidence to the notion that mon-
telukast can inhibit neurological and mental decline in 
humans. The medicine is considered relatively safe, and 
is therefore of interest for further investigation regarding 
healthy aging.
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